{
  "doc_id": "Sorafenib+(Nexavar)+bij+Hepatocellulair+carcinoom-gevorderd+niercelcarcinoom (1)",
  "created_date": "2007",
  "country": "NL",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "EJ EJ '2007 2007 Farmacec/doorknoum doorknoum PAK/Cheung Cheung (020) Insurance Insurance (CVZ) be be • stage. stage. • a a (intention) specification specification (palliative palliative treatment) description description (an invasive treatment) Consideration Consideration CVz: you you xavar®) follows follows e: urnum urnum snum-",
      "start_page": 1,
      "end_page": 4
    },
    {
      "heading": "__MEDTERM0_ (Nexavar®)",
      "text": "Fax Fax (020) E-mail E-mail info@Tel. Tel. (200) te te (z. z.nl) pag. pag. ud: indication indication ______",
      "start_page": 4,
      "end_page": 6
    },
    {
      "heading": "1. Introduction",
      "text": "of of Nexavar® carcinoma. carcinoma.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "indication. indication.",
      "text": "__MEDTERM0_ __MEDTERM0_ (Nexavar®) Film-coated tablet: 200 mg __MENTERM0_(tosylate) the the patient'treatment treatment ́the the therapy'Treating Treating patients;existing existing treatment_MEDterM9(hoden). treatment treatment ___",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "3. Conclusion",
      "text": "or or (continuation of) Report Report EU/ 1/ 97/ 030/",
      "start_page": 7,
      "end_page": 8
    },
    {
      "heading": "1. Summary",
      "text": "__MEDTERM0_ __MEDTERM0_ (Nexavar®) provided provided ___=following following conclusions: have have ______",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "2. Introduction",
      "text": "Nexavar Nexavar (_MEDTERM0__) mg mg / / /tumour. tumour.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "view view assessment",
      "text": "2. 2.4:1. 1.6/0. 0.3/Europe Europe were: hepatitis C (60-70%), alcohol consumption (20%), hepatitis B (10-15%), and other - treatment treatment (__MEDTERM1_palliative __MEDTERM1_palliative care). physical physical condition; expansion expansion to",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "4. Therapeutic value",
      "text": "measures measures were: significantly significantly longer; months months (table 1). ___ ___ verwarrenderM0/than than placebo: 9 9 (__ELDERM28___hepatitic __ELDERM28___hepatitic carcinoma___pooledderM28); for for p/e/in in 52% (versus 54% placebo placebo group; p = 0.49). taking taking __ELDERM0/treated treated . adolescents. adolescents. Conclusion: of of _/ELDERM00/ mg mg (200 200 mg) two two hours",
      "start_page": 10,
      "end_page": 12
    },
    {
      "heading": "considerations. considerations.",
      "text": "price price (in €) AIP Dosage (in DDD) Cost (in euro) not not established; 200 200 mg* recommended posology: daily daily (= 4 tablets/day) *Bron: None. None.",
      "start_page": 12,
      "end_page": 13
    },
    {
      "heading": "of of __MEDTERM0_",
      "text": "6.a. Manufacturer'treatment treatment failure;patients patients compared",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "7. CFH advice",
      "text": "or or (continuation of) localization. localization.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "8. Literature",
      "text": "__MEDTERM0_ __MEDTERM0_ (Nexavar®). London: EMEA; of of __ELDERM0_(Nexavar®)hepatocellular hepatocellular carcinoma",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "1. Introduction",
      "text": "and and - expanded expanded ___>medterm4_the indication: The The CFH2-dissolved/disease",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "of of Patients",
      "text": "to to 30% for for treatment;___MEDTERM3_S); impairment impairment and/ of of NCI-CTC",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "2.3 Costs",
      "text": "cost cost €tablet tablet (P. P.). __EDTERM2___ __EDTERM2___ __DFORDERM1_(day day (and and clawback) be be either: _",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Consequencing Consequencing Estimate",
      "text": "for for treatment;_EDTERM6/following following data: higher higher risk",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "4. Conclusions",
      "text": "maximum maximum (more) 2 2 -conditions. conditions.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "5. References",
      "text": "__MEDTERM0_ __MEDTERM0_ (Nexavar®). __MDTERM00_ __MDTERM00_ (Netherlands®) 2007. 2007.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "headed headed <points points assessment>",
      "text": "Row 1: DrugNexavar (_MEDTERM0_) Road 2: mg mg ___/Toselm0_(tosylate) Rog Rog 3: Row Row 4: with with other",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "headed headed <5. References>",
      "text": "Row 1: GVS. GVS. (% market penetration)carcinoma carcinoma (million euros)Roy 2: Year 1 ( 33%)0.7 - Row Row 3: Year 2 (66%)Row Row 4: Year 3 (100%)2. 2.7",
      "start_page": 15,
      "end_page": 15
    }
  ]
}